New target for breast cancer treatment - LINC01271

In recent years, many large-scale genome-wide studies have shown that large amounts of RNA trouted from human and mouse genomes lack protein coding capabilities but play an indispensable role.
, long-chain non-coded RNA (lncRNA) is thought to play a key role in a variety of biological processes.
lncRNA is expressed in a tissue-specific or cell-specific manner and participates in a variety of gene regulatory path path path roads.
2016, scientists at cold spring harbor labs found some RNA molecules in breast cancer cells that are more commonly expressed in breast cancer cells than in the same type of non-cancer cells, all of which are lncRNAs.
in a new study, they studied one of the lncRNA MaTAR25 (Mammary Tumor Associated RNA 25).
results show that knocking out MaTAR25 causes cancer cells to multiply, migrate and attack less.
and the increased expression of the human directly related to MaTAR25, LINC01271, was associated with poor prognostic and metastasis in patients.
study was published on December 22nd in Nature Communications.
source: Nature Communications researchers first knocked out MaTAR25 in highly invasive 4T1 triple-negative breast cancer cells and found that MaTAR25 knocks cells significantly less proliferating, migrating, and invasive than 4T1 control cells.
effects of MaTAR25 in in vitro experiments (Source: Nature Communications) Followed by several in vivo studies that have also observed that the knock-off of the MaTAR25 gene can reduce tumor growth and metastasis.
the effects of MaTAR25 in in vivo experiments (Source: Nature Communications) "Oncology histology tests have found a large number of necrotic tumors, which means that many cells die after RNA is degraded.
suggests that MaTAR25 has some potential as a therapeutic target.
Spector, author of the paper' newsletter, said.
further studies suggest that these effects may be related to changes in the activity of the downstream gene Tensin1 (Tns1).
Tns1 protein is a key component of adhesive plaques that connect signaling between the extracellular substation and the cytostic skeleton, affecting the cell's movement and growth regulation path.
knock-out of MaTAR25 can cause Tns1 expression to decrease, leading to recombination of the cytostebrae, reducing lesions adhesion and cell micro-fluff.
indicates that Tns1 is a key downstream target for MaTAR25.
in order to translate these results into future human clinical applications, researchers identified and identified the direct human ogeneous of MaTAR25 and found that the expression of LINC01271's isosides could save MaTAR25 from knocking off cell proliferation esplies.
and in the patient's breast tumor slice, LINC01271 expression level increased with the increase of breast cancer stage, and the lung and lymph node metastasis of the same patient showed higher LINC01271 expression than the primary tumor.
suggests that LINC01271 is a potential therapeutic target for breast cancer progress and metastasis.
the expression of LINC01271 in breast cancer and pulmonary metastasis (Source: Nature Communications) Overall, these data reveal that MaTAR25 and its human direct estration, LINC01271, are very promising therapeutic targets.
team is now studying whether antonymic oligonucleotides targeted at LINC01271 can interfere with tumor growth and metastasis in human-sourced breast cancer models.
: 1 s Chang, KC., Diermeier, S. D., Yu, A. T. et al. MaTAR25 lncRNA regulates the Tensin1 gene to impact breast cancer progression. Nature Communications (2020) 2 s Regulatory RNAs promote breast cancer metastasis (Source: Cold Spring Harbor Laboratory)